KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teladoc Health (TDOC) Current Leases (2021 - 2023)

Historic Current Leases for Teladoc Health (TDOC) over the last 3 years, with Q1 2023 value amounting to $13.0 million.

  • Teladoc Health's Current Leases changed N/A to $13.0 million in Q1 2023 from the same period last year, while for Mar 2023 it was $13.0 million, marking a year-over-year change of. This contributed to the annual value of $13.6 million for FY2022, which is 713.33% up from last year.
  • Teladoc Health's Current Leases amounted to $13.0 million in Q1 2023.
  • In the past 5 years, Teladoc Health's Current Leases ranged from a high of $13.6 million in Q4 2022 and a low of $12.7 million during Q4 2021
  • Over the past 3 years, Teladoc Health's median Current Leases value was $12.9 million (recorded in 2022), while the average stood at $13.0 million.
  • Within the past 5 years, the most significant YoY rise in Teladoc Health's Current Leases was 713.33% (2022), while the steepest drop was 713.33% (2022).
  • Quarter analysis of 3 years shows Teladoc Health's Current Leases stood at $12.7 million in 2021, then increased by 7.13% to $13.6 million in 2022, then dropped by 4.66% to $13.0 million in 2023.
  • Its Current Leases was $13.0 million in Q1 2023, compared to $13.6 million in Q4 2022 and $12.9 million in Q3 2022.